Study shows how Paxlovid resistance emerges in persistent infections
Paxlovid is still a highly effective treatment for most people infected with SARS-CoV-2 and the drug prevents many hospitalizations and deaths from COVID.
Sep 11, 2023
0
32
Paxlovid is still a highly effective treatment for most people infected with SARS-CoV-2 and the drug prevents many hospitalizations and deaths from COVID.
Sep 11, 2023
0
32
Herpes is not only unpleasant but it can, in some cases, also have dangerous complications and life-threatening consequences. In the journal Angewandte Chemie, a research team has now introduced a completely new approach ...
Sep 7, 2023
0
67
Researchers have developed an automated version of the viral plaque assay, the gold-standard method for detecting and quantifying viruses. The new method uses time-lapse holographic imaging and deep learning to greatly reduce ...
Aug 31, 2023
0
7
While conventional flu vaccines are designed to anticipate the influenza strains projected to dominate in the next flu season, they're only partially effective. And while antiviral drugs are available to treat active flu ...
Aug 15, 2023
0
89
Two oral drugs, molnupiravir and paxlovid (nirmatrelvir/ritonavir), provide equivalent therapeutic benefit in preventing severe COVID-19 in animal models, but only molnupiravir efficiently blocked SARS-CoV-2 transmission ...
Aug 9, 2023
0
2
Just as bacteria can develop antibiotic resistance, viruses can also evade drug treatments. Developing therapies against these microbes is difficult because viruses often mutate or hide themselves within cells. But by mimicking ...
Aug 2, 2023
0
1
The ongoing COVID-19 pandemic has raised global concern on public health. There are major challenges ahead to develop new therapeutics and vaccines for difficult-to-target pathogens, for which we urgently need a better understanding ...
Jul 25, 2023
0
1
Salk Institute researchers, in collaboration with the National Institutes of Health, have discovered the molecular mechanisms by which the human immunodeficiency virus (HIV) becomes resistant to Dolutegravir, one of the most ...
Jul 21, 2023
0
11
In a study published in Nature Cell Biology, Australian researchers, led by Professor Jose Polo from Monash University and the University of Adelaide and University of Melbourne's Professor Kanta Subbarao from the Peter Doherty ...
Jul 13, 2023
0
19
When it comes to COVID, people living in disadvantaged communities are hit with a triple whammy. First, they're more likely to get infected, and when sick, are more likely to have serious disease. Second, they're more likely ...
Jun 22, 2023
0
2